IL305337A - A therapeutic regimen containing an immediate release dose of an S1P modulator - Google Patents

A therapeutic regimen containing an immediate release dose of an S1P modulator

Info

Publication number
IL305337A
IL305337A IL305337A IL30533723A IL305337A IL 305337 A IL305337 A IL 305337A IL 305337 A IL305337 A IL 305337A IL 30533723 A IL30533723 A IL 30533723A IL 305337 A IL305337 A IL 305337A
Authority
IL
Israel
Prior art keywords
siponimod
day
dosage form
patient
treatment
Prior art date
Application number
IL305337A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL305337(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL305337A publication Critical patent/IL305337A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL305337A 2014-04-10 2015-04-08 A therapeutic regimen containing an immediate release dose of an S1P modulator IL305337A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
IL305337A true IL305337A (en) 2023-10-01

Family

ID=52988364

Family Applications (2)

Application Number Title Priority Date Filing Date
IL305337A IL305337A (en) 2014-04-10 2015-04-08 A therapeutic regimen containing an immediate release dose of an S1P modulator
IL247986A IL247986A0 (en) 2014-04-10 2016-09-22 A therapeutic regimen containing an immediate release dose of an s1p modulator

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL247986A IL247986A0 (en) 2014-04-10 2016-09-22 A therapeutic regimen containing an immediate release dose of an s1p modulator

Country Status (16)

Country Link
US (4) US20170027907A1 (2)
EP (3) EP3129020A1 (2)
JP (1) JP6674903B2 (2)
KR (2) KR20220156981A (2)
CN (2) CN106456552A (2)
AU (2) AU2015246036A1 (2)
CA (1) CA2943598C (2)
CL (1) CL2016002562A1 (2)
IL (2) IL305337A (2)
MX (1) MX2016013245A (2)
PH (1) PH12016501965A1 (2)
RU (2) RU2715734C2 (2)
SG (1) SG11201607894RA (2)
TW (1) TW201622721A (2)
WO (1) WO2015155709A1 (2)
ZA (1) ZA201606519B (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (2) 2014-01-24 2018-02-24
EP3129020A1 (en) * 2014-04-10 2017-02-15 Novartis AG S1p modulator immediate release dosage regimen
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3687531A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
CA3073910A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
HUE070049T2 (hu) * 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
WO2020018547A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120115840A1 (en) * 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
TW201028143A (en) * 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
NZ598534A (en) * 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator
JP6111202B2 (ja) * 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
EP3129020A1 (en) * 2014-04-10 2017-02-15 Novartis AG S1p modulator immediate release dosage regimen

Also Published As

Publication number Publication date
SG11201607894RA (en) 2016-10-28
RU2016143979A3 (2) 2018-11-12
KR20160141841A (ko) 2016-12-09
AU2020203107A1 (en) 2020-05-28
RU2715734C2 (ru) 2020-03-03
US20190054065A1 (en) 2019-02-21
EP4074312B1 (en) 2026-02-25
PH12016501965A1 (en) 2017-01-09
EP4074312A1 (en) 2022-10-19
EP4074312C0 (en) 2026-02-25
RU2016143979A (ru) 2018-05-14
CA2943598C (en) 2023-03-07
AU2015246036A1 (en) 2016-10-13
CN116650467A (zh) 2023-08-29
AU2020203107B2 (en) 2021-10-21
MX2016013245A (es) 2017-01-16
TW201622721A (zh) 2016-07-01
CA2943598A1 (en) 2015-10-15
JP6674903B2 (ja) 2020-04-01
US20170027907A1 (en) 2017-02-02
EP3831378A1 (en) 2021-06-09
IL247986A0 (en) 2016-11-30
EP3129020A1 (en) 2017-02-15
US20220016076A1 (en) 2022-01-20
US20250041266A1 (en) 2025-02-06
ZA201606519B (en) 2017-11-29
WO2015155709A1 (en) 2015-10-15
JP2017510607A (ja) 2017-04-13
RU2020107732A (ru) 2020-03-30
CL2016002562A1 (es) 2017-07-28
CN106456552A (zh) 2017-02-22
KR20220156981A (ko) 2022-11-28

Similar Documents

Publication Publication Date Title
US20250041266A1 (en) S1p modulator immediate release dosage regimen
TWI632909B (zh) 治療阿滋海默症之方法以及其醫藥組成物
US12161758B2 (en) Modified release formulations and uses thereof
US12533340B2 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20070155759A1 (en) Pharmaceutical uses
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
JP2698865B2 (ja) 筋緊張性ジストロフィー症治療剤
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
TW202322816A (zh) 篩選 vmat2 抑制劑之方法
US20050228052A1 (en) Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
CA2973540C (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
TW202527911A (zh) 用於治療猝睡症的化合物
US20220151938A1 (en) Tablet for use in treating huntington's disease and method of making the same